Arrowhead Pharms

ARWR NASDAQ
28.16
+0.36
+1.30%
After Hours: 28.26 +0.1 +0.36% 19:59 07/16 EDT
Open
27.81
Prev Close
27.80
High
28.33
Low
27.60
Volume
737.52K
Avg Vol (3M)
2.05M
52 Week High
28.84
52 Week Low
10.41
% Turnover
0.78%
Market Cap
2.67B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Arrowhead Pharms ARWR stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
MORE >

Recently

Name
Price
%Change